Sarafotoxin S6a is primarily used in biomedical research due to its potent vasoconstrictive properties. It acts as a selective agonist for endothelin receptors, particularly ET_A and ET_B, making it a valuable tool for studying vascular function and endothelin-mediated signaling pathways. Researchers use it to induce controlled hypertension in experimental models to investigate cardiovascular diseases and the effectiveness of antihypertensive drugs. It is also employed in studies exploring smooth muscle contraction, especially in blood vessels and bronchial tissues. Due to its high potency and specificity, it helps in characterizing receptor subtypes and developing targeted therapies for conditions involving endothelin dysregulation, such as pulmonary arterial hypertension and chronic kidney disease.